EPZM - Epizyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.73
-0.05 (-0.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.78
Open12.77
Bid12.74 x 800
Ask12.75 x 1200
Day's Range12.34 - 12.89
52 Week Range5.14 - 16.59
Volume409,910
Avg. Volume890,684
Market Cap1.156B
Beta (3Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Here's Why Epizyme Rose 103.7% in the First Half of 2019
    Motley Fool8 days ago

    Here's Why Epizyme Rose 103.7% in the First Half of 2019

    The company put a clinical hold from 2018 behind it and submitted its first-ever new drug application.

  • Epizyme Announces Positive Interim Data on Lead Candidate
    Zacks26 days ago

    Epizyme Announces Positive Interim Data on Lead Candidate

    Epizyme (EPZM) announces positive interim data from an ongoing phase II study of its lead candidate, tazemetostat.

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

    For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...

  • Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)
    Insider Monkeylast month

    Hedge Funds Have Never Been This Bullish On Epizyme Inc (EPZM)

    We can judge whether Epizyme Inc (NASDAQ:EPZM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

  • Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?
    Zackslast month

    Why Is Epizyme (EPZM) Up 10.9% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure
    Zacks2 months ago

    Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure

    Epizyme (EPZM) submits an NDA filing for tazemetostat to the FDA with an objective to treat patients suffering metastatic epithelioid sarcoma, not eligible for curative surgery. Shares inch up.

  • Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition
    American City Business Journals2 months ago

    Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition

    Cambridge-based Epizyme is now awaiting FDA for approval for its epigenetics first product, tazemetostat, with plans to quickly expand its applications.

  • Will Epizyme to Surge Higher?
    Zacks2 months ago

    Will Epizyme to Surge Higher?

    As of late, it has definitely been a great time to be an investor Epizyme.

  • Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?
    Zacks2 months ago

    Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?

    Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.

  • Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates

    Epizyme (EPZM) delivered earnings and revenue surprises of 17.02% and 601.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Epizyme: 1Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had a loss of 39 cents per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...

  • If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today
    Simply Wall St.3 months ago

    If You Had Bought Epizyme (NASDAQ:EPZM) Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today

    It is a pleasure to report that the Epizyme, Inc. (NASDAQ:EPZM) is up 39% in the last quarter. But over the last half decade, the stock has not performed well. In fact, the share price is down 39%, which falls well short o...

  • Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report?
    Zacks4 months ago

    Why Is Epizyme (EPZM) Down 14.4% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Does Epizyme, Inc.’s (NASDAQ:EPZM) CEO Salary Compare Well With Others?
    Simply Wall St.4 months ago

    Does Epizyme, Inc.’s (NASDAQ:EPZM) CEO Salary Compare Well With Others?

    Rob Bazemore has been the CEO of Epizyme, Inc. (NASDAQ:EPZM) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that,Read More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of EPZM earnings conference call or presentation 26-Feb-19 1:30pm GMT

    Q4 2018 Epizyme Inc Earnings Call

  • Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4
    Zacks5 months ago

    Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4

    Epizyme (EPZM) reports narrower-than-expected loss in the fourth quarter of 2018.

  • 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
    Zacks5 months ago

    5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

    Let us take a look at five favorable stocks, poised to beat estimates this earnings season.

  • Epizyme to File NDA for Tazemetostat in Follicular Lymphoma
    Zacks6 months ago

    Epizyme to File NDA for Tazemetostat in Follicular Lymphoma

    Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.

  • Why Epizyme Stock Rose ~33% on January 4
    Market Realist6 months ago

    Why Epizyme Stock Rose ~33% on January 4

    Why Epizyme Stock Rose ~32% on January 4 ## Stock performance On January 4, Epizyme (EPZM) stock closed at $7.94, which represents ~32.78% growth from its prior close of $5.98 on January 3, 2019. On January 3, Epizyme stock fell 10.34% to reach $5.98 from its prior-day closing price of $6.67 on January 2. Epizyme stock fell from $12.55 at the close of market on December 29, 2017, to reach $6.16 on December 31, 2018, which was a ~51% decline in 2018. Epizyme’s price on January 4 is ~63% below its 52-week high of $21.4 on March 13, 2018. The company hit its 52-week low of $5.14 on December 24, 2018. ## Reason for stock price rise On January 4, Epizyme announced that it found a path for accelerated approval by the US FDA (Food and Drug Administration) of its investigational drug tazemetostat for the treatment of individuals with relapsed or refractory follicular lymphoma (or FL) who may be with or without EZH2 activating mutations. Epizyme already conducted a meeting with the FDA to discuss the FL registration strategy with the present patient population in the company’s ongoing phase 2 trial. After discussion with the FDA, the company specified the registration strategy for tazemetostat. The company can register patients in both types of EZH2 mutation and patients with wild-type FL with disease progression after two or more lines of therapy. Epizyme expects to submit an NDA (new drug application) to the FDA for the said indications by the fourth quarter of 2019. Epizyme already completed the enrollment of the phase 2 trial for the evaluation of safety and efficacy of tazemetostat for the said indications. Epizyme also anticipates submitting its first NDA to the FDA for tazemetostat for the treatment of individuals with epithelioid sarcoma under accelerated approval pathway in the second quarter of 2019. Epizyme has plans to initiate clinical trials for label expansion of tazemetostat and also evaluate the drug along with other combination therapies. Epizyme sees potential in the drug for the treatment of multiple cancer types. The company plans to initiate the study of tazemetostat for small-cell lung cancer, triple-negative breast cancer, ovarian cancer, and castration-resistant prostate cancer by the second half of 2019. ## Analysts’ recommendations Of the ten analysts tracking Epizyme in January 2019, four of them recommended a “strong buy,” while another four analysts recommended a “buy” rating. Two analysts recommended a “hold” rating for Epizyme in January 2019. The company had a consensus 12-month target price of $19.44, which represents a ~144.84% return on investment over the next 12 months.

  • Why GameStop, Novavax, and Epizyme Jumped Today
    Motley Fool6 months ago

    Why GameStop, Novavax, and Epizyme Jumped Today

    It was a great day for the overall market. Find out why these stocks stood out.

  • Here's Why Epizyme's Shares Are Surging 19.6% Higher Today
    Motley Fool6 months ago

    Here's Why Epizyme's Shares Are Surging 19.6% Higher Today

    A new update on its epigenetics drug, tazemetostat, has kindled investor optimism.

  • Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds?
    Insider Monkey7 months ago

    Is Epizyme Inc (EPZM) Going to Burn These Hedge Funds?

    “October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being ’08 and the Crash of ’87. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?
    Zacks8 months ago

    Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report?

    Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3
    Zacks8 months ago

    Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3

    Epizyme (EPZM) incurs narrower-than-expected loss in the third quarter of 2018. The company is on track to submit an NDA for tazemetostat in epithelioid sarcoma in the first half of 2019.